GlobeNewswire Inc.··Hagens BermanImmunityBio Plunges 21% After FDA Warning Over Unsupported Cancer Claims
ImmunityBio shares plunge 21% after FDA warning over unsupported cancer treatment claims, erasing $2 billion in market value and triggering securities litigation.
IBRXsecurities class actionstock price decline